2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
6
Brain Neoplasms
3
Neoplasms
2
Lung Neoplasms
2
Thrombophilia
1
Stomatitis
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Periodontitis
1
Patient Satisfaction
1
Neoplasms, Plasma Cell
1
Motor Activity
1
Liver Neoplasms
1
Liver Diseases
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Febrile Neutropenia
1
EGFR-Mutant Lung Cancer
1
Deglutition Disorders
1
Communication Disorders
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Diseases
1
Blood Coagulation Disorders
1
Advanced Breast Cancer
1
Interventions
Oxaliplatin
46
Gemcitabine
45
Fluorouracil
40
Capecitabine
31
pembrolizumab
30
Leucovorin
29
Docetaxel
27
Cisplatin
25
Paclitaxel
23
Irinotecan
18
Carboplatin
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
17
Radiotherapy
16
Pemetrexed
15
Albumin-Bound Paclitaxel
15
Nivolumab
13
Ramucirumab
11
Cyclophosphamide
11
Drug Therapy
9
Trastuzumab
8
Erlotinib Hydrochloride
8
zolbetuximab
7
Taxes
7
Radiosurgery
7
trastuzumab deruxtecan
6
cemiplimab
6
Blood Specimen Collection
6
regorafenib
5
durvalumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Lead
×
Clear all
NCT01808638
2016-03-11
Atu027-I-02
Silence Therapeutics GmbH
Phase 1/2
Completed
29 enrolled